e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
暂无分享,去创建一个
T. Beccari | S. Hunot | F. Curcio | E. Albi | S. Cataldi | I. Ferri | A. Sidoni | M. Codini | F. Ambesi-Impiombato | François-Pierre Légeron | Paola Siccu
[1] B. Kleinschmidt-DeMasters,et al. Dual use of E-cadherin and D2-40 immunostaining in unusual meningioma subtypes. , 2015, American journal of clinical pathology.
[2] K. Gupta,et al. Mechanism of Nanotization-Mediated Improvement in the Efficacy of Caffeine Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism. , 2015, Journal of biomedical nanotechnology.
[3] J. Forrester,et al. Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease , 2015, Glia.
[4] Jia-wei Zhou,et al. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target , 2015, Translational Neurodegeneration.
[5] M. Kaplitt,et al. The tumor suppressor PTEN regulates motor responses to striatal dopamine in normal and Parkinsonian animals , 2015, Neurobiology of Disease.
[6] P. De Baetselier,et al. E-cadherin expression in macrophages dampens their inflammatory responsiveness in vitro, but does not modulate M2-regulated pathologies in vivo , 2015, Scientific Reports.
[7] N. Sikka,et al. Expression and Significance of Cadherins and Its Subtypes in Development and Progression of Oral Cancers: A Review. , 2015, Journal of clinical and diagnostic research : JCDR.
[8] E. Fornasiero,et al. Cadherins as regulators of neuronal polarity , 2015, Cell adhesion & migration.
[9] Qing Zhou,et al. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis , 2015, Medical Oncology.
[10] C. Niu,et al. Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson’s disease , 2015, Neurological Sciences.
[11] O. Barreiro,et al. Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial–mesenchymal transition and fibrosis during peritoneal dialysis , 2014, EMBO molecular medicine.
[12] E. Hirsch,et al. Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease , 2014, Journal of Neuroinflammation.
[13] E. Hirsch,et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease , 2013, Scientific Reports.
[14] T. Zuo,et al. Involvement of N-cadherin in the protective effect of glial cell line-derived neurotrophic factor on dopaminergic neuron damage. , 2013, International journal of molecular medicine.
[15] F. Curcio,et al. Observing the mouse thyroid sphingomyelin under space conditions: a case study from the MDS mission in comparison with hypergravity conditions. , 2012, Astrobiology.
[16] F. Curcio,et al. The thyroid lobes: the different twins. , 2012, Archives of biochemistry and biophysics.
[17] Juliette van Steenwinckel,et al. Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system , 2011, Journal of neurochemistry.
[18] S. Shimohama,et al. N-cadherin Regulates p38 MAPK Signaling via Association with JNK-associated Leucine Zipper Protein , 2010, The Journal of Biological Chemistry.
[19] F. Cicchetti,et al. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions , 2009, Journal of neurochemistry.
[20] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[21] M. V. Magni,et al. Lipid microdomains in cell nucleus. , 2008, Molecular biology of the cell.
[22] D. Surmeier,et al. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. , 2008, Parkinsonism & related disorders.
[23] J. Potashkin,et al. MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9 , 2007, Brain Research.
[24] E. Hirsch,et al. The Role of Glial Reaction and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[25] S. Mandel,et al. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron , 2002, Neurotoxicity Research.
[26] S. Totterdell,et al. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment , 2001, Neuroscience.
[27] T. Nagatsu,et al. Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.
[28] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.